CIBC Private Wealth Group
ALBO

CIBC Private Wealth Group’s Albireo Pharma Inc ALBO Stock Holding History

CIBC Private Wealth Group’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$51K – 2108
2017
Q4 		$51K Buy
+2,000
New +$50.7K ﹤0.01% 1182

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CIBC Private Wealth Group's ALBO Position: Q1 2018 in Review

CIBC Private Wealth Group sold out of Albireo Pharma Inc (ALBO) in Q1 2018, closing a stake of 2,000 shares — an estimated $51K sold.

CIBC Private Wealth Group first reported a position in ALBO in Q4 2017 and held it in 1 quarter. The position peaked at $51K in Q4 2017. 50 funds tracked by Wall St. Rank hold ALBO as of Q1 2018.

  • CIBC Private Wealth Group reported no remaining Albireo Pharma Inc position as of Q1 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 2,000 Albireo Pharma Inc shares in Q1 2018, an estimated $51K.
  • CIBC Private Wealth Group first reported a position in Albireo Pharma Inc in Q4 2017 and held it in 1 quarter.
  • CIBC Private Wealth Group's Albireo Pharma Inc position peaked at $51K in Q4 2017.
  • 50 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2018.

Based on CIBC Private Wealth Group's 13F filing for Q1 2018, filed 17 May 2018.